Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 M4HYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy1dIZKSzVyPUCuNFAxOjh5IN88US=> MlPjV2FPT0WU
LC-2-ad MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi1RZkyUUN3ME2wMlAxODNzNzFOwG0> NFrQc3pUSU6JRWK=
RL95-2 NYPWVodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXEfVJKSzVyPUCuNFAxPjZ6IN88US=> M{fOeHNCVkeHUh?=
MZ1-PC NVH2Xo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMECwO|I6KM7:TR?= MnfwV2FPT0WU
TE-8 NV3kNnZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\YTWM2OD1yLkCwNVE4KM7:TR?= NX:w[nU6W0GQR1XS
SW954 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMECxNVkh|ryP NEH6eJBUSU6JRWK=
TE-11 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W1WWlEPTB;MD6wNFEzOyEQvF2= NWj2VHJ2W0GQR1XS
PSN1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy3U|lJUUN3ME2wMlAxOTNizszN M1rPVHNCVkeHUh?=
MOLT-4 NHnnUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LqXWlEPTB;MD6wNFE1QSEQvF2= MWHTRW5ITVJ?
697 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMECxOUDPxE1? Mlz4V2FPT0WU
ETK-1 M1jnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHYTWM2OD1yLkCwNVUzKM7:TR?= MkDRV2FPT0WU
TE-10 NWDWWHd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMECxOVQh|ryP NETMSJRUSU6JRWK=
HUTU-80 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMECxOlgh|ryP MoC4V2FPT0WU
NTERA-S-cl-D1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV64bYNRUUN3ME2wMlAxOjB7IN88US=> M4jGcHNCVkeHUh?=
MFH-ino M{e1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMECyOlgh|ryP MkHZV2FPT0WU
IA-LM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMECyPEDPxE1? NXiweYVqW0GQR1XS
MC116 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO5RoRkUUN3ME2wMlAxOjh7IN88US=> M4DwNnNCVkeHUh?=
RKO MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXyVmVKSzVyPUCuNFAzQThizszN MVvTRW5ITVJ?
MRK-nu-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMECyPVkh|ryP NILsVmFUSU6JRWK=
VA-ES-BJ MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7FOodvUUN3ME2wMlAxOyEQvF2= MmXzV2FPT0WU
KALS-1 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn70TWM2OD1yLkCwN|A5KM7:TR?= NEfFSWtUSU6JRWK=
BB30-HNC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMECzNVQh|ryP NVK3O3ppW0GQR1XS
ACN MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMECzNVYh|ryP M{jIU3NCVkeHUh?=
TE-9 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTSTWM2OD1yLkCwN|I3KM7:TR?= M2TzXHNCVkeHUh?=
SIG-M5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi3dWs5UUN3ME2wMlAxOzJ5IN88US=> NX6yZo9OW0GQR1XS
no-10 NVTlbphTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LGV2lEPTB;MD6wNFM3OiEQvF2= MnX5V2FPT0WU
EW-1 NITDclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnaVIZbUUN3ME2wMlAxOzdzIN88US=> M1zzZ3NCVkeHUh?=
SK-LMS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomwTWM2OD1yLkCwOFAyKM7:TR?= M1TEZXNCVkeHUh?=
GT3TKB NGqxRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2wTWM2OD1yLkCwOFM1KM7:TR?= M3vWNXNCVkeHUh?=
ES4 NYP4SnY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHIOGp3UUN3ME2wMlAxPDR7IN88US=> MoK0V2FPT0WU
IMR-5 NGfHcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEC0OUDPxE1? NWfOOllkW0GQR1XS
NCI-H1648 NF;XUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEC0Olkh|ryP M3zpeHNCVkeHUh?=
MV-4-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fjW2lEPTB;MD6wNFQ4PSEQvF2= M1LUbXNCVkeHUh?=
SK-UT-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;QTWM2OD1yLkCwOFgh|ryP NGP3fJhUSU6JRWK=
NB13 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMEC0PVEh|ryP NEjVU5RUSU6JRWK=
DJM-1 M1HqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojpTWM2OD1yLkCwOVMh|ryP NH7RdlZUSU6JRWK=
ES8 M4C2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEC1N|gh|ryP NEH6c5JUSU6JRWK=
TE-6 M{ntc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIeySVhKSzVyPUCuNFA2PyEQvF2= NIi0[VNUSU6JRWK=
KS-1 M2L3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\5SY9KSzVyPUCuNFA2QDJizszN NEHrRndUSU6JRWK=
TE-1 M2TYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXNTWM2OD1yLkCwOlA3KM7:TR?= MkHhV2FPT0WU
ATN-1 NYLnS|k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEC2NFkh|ryP NHP1WpZUSU6JRWK=
A4-Fuk MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r2e2lEPTB;MD6wNFYyOSEQvF2= NGDjW2VUSU6JRWK=
ALL-PO Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6zVZpyUUN3ME2wMlAxPjNizszN MkC4V2FPT0WU
BE-13 NH\pbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEC2N|Yh|ryP MlrLV2FPT0WU
KM12 M2PGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3WmtKSzVyPUCuNFA3OzdizszN Ml;YV2FPT0WU
NOS-1 NGHCfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnSZ5RKSzVyPUCuNFA3PSEQvF2= M3PkW3NCVkeHUh?=
SW962 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i0VGlEPTB;MD6wNFY3OiEQvF2= NYKxRVJ[W0GQR1XS
OCUB-M M3rWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ZfY4{UUN3ME2wMlAxPjZ{IN88US=> MmPHV2FPT0WU
NCI-H510A NX:4NXQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XIbWlEPTB;MD6wNFY3PSEQvF2= MkXlV2FPT0WU
EW-16 M4Xhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrSfpZMUUN3ME2wMlAxPjl2IN88US=> M4nNPXNCVkeHUh?=
KGN NHH2UINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW3TWM2OD1yLkCwO|EzKM7:TR?= NU\KbFBEW0GQR1XS
LS-411N M{jHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLtXmFiUUN3ME2wMlAxPzF5IN88US=> MWPTRW5ITVJ?
Becker MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjoTWM2OD1yLkCwO|Ih|ryP NXfBUYpvW0GQR1XS
HC-1 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDHO2FKSzVyPUCuNFA4OjFizszN Mof5V2FPT0WU
CESS M4P1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PHNmlEPTB;MD6wNFc{PyEQvF2= MlvXV2FPT0WU
KURAMOCHI MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LBXGlEPTB;MD6wNFc1QCEQvF2= NH3xPZJUSU6JRWK=
TGBC24TKB M1\Cdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEC3OVIh|ryP M4fIVXNCVkeHUh?=
SW982 MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEC3OlYh|ryP M2fSSnNCVkeHUh?=
HCE-4 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofkTWM2OD1yLkCwO|Y4KM7:TR?= NVzBU5J3W0GQR1XS
LOUCY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP4TWM2OD1yLkCwO|c2KM7:TR?= MlixV2FPT0WU
8-MG-BA MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLqTWM2OD1yLkCwO|k3KM7:TR?= MUPTRW5ITVJ?
HT-144 M1fJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f3cGlEPTB;MD6wNFgh|ryP MWrTRW5ITVJ?
LXF-289 NXTE[5ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3XTWM2OD1yLkCwPFE5KM7:TR?= NIjBUI1USU6JRWK=
RS4-11 M{G4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInoTHZKSzVyPUCuNFA5OzZizszN M2PEV3NCVkeHUh?=
DEL NVfDZZJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEC4OFUh|ryP NXvH[Ic5W0GQR1XS
OCI-AML2 M3SyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzcmlEPTB;MD6wNFg2OiEQvF2= M1rDcnNCVkeHUh?=
CCRF-CEM M4fobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G3PGlEPTB;MD6wNFg4OSEQvF2= NGLZb2pUSU6JRWK=
A388 M174Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LmfWlEPTB;MD6wNFg4PCEQvF2= NH3sVYZUSU6JRWK=
KNS-42 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2flV2lEPTB;MD6wNFg6OSEQvF2= MVTTRW5ITVJ?
OVCAR-4 M1LiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rSZ2lEPTB;MD6wNFkxPCEQvF2= NHu1UYZUSU6JRWK=
NCI-H1355 NF36dYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG1TWM2OD1yLkCwPVE1KM7:TR?= NXvrfXloW0GQR1XS
BL-70 NVTqd2dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEC5N{DPxE1? MWTTRW5ITVJ?
BL-41 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEC5N|Qh|ryP NF;UflBUSU6JRWK=
A101D M{\XTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvKTWM2OD1yLkCwPVYh|ryP MofCV2FPT0WU
HL-60 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMEC5OlYh|ryP NVLwd5NOW0GQR1XS
COR-L279 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX6TWM2OD1yLkCwPVk6KM7:TR?= M1;IOXNCVkeHUh?=
NCI-SNU-16 M2HZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWzbVlKSzVyPUCuNFExODhizszN MkX1V2FPT0WU
Calu-6 M4DiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PhT2lEPTB;MD6wNVAyOiEQvF2= NXHqXmFoW0GQR1XS
SR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLFVHB2UUN3ME2wMlAyODJ4IN88US=> MmnZV2FPT0WU
QIMR-WIL NYP1eGFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHEU45bUUN3ME2wMlAyODN|IN88US=> M4PNfXNCVkeHUh?=
LB647-SCLC NVXMSmZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P0OmlEPTB;MD6wNVA2OSEQvF2= MkW1V2FPT0WU
RPMI-8226 NV3qS4NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\5OWRCUUN3ME2wMlAyOTB{IN88US=> MlvLV2FPT0WU
SK-PN-DW NHjzWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT4TWM2OD1yLkCxNVEzKM7:TR?= MoWwV2FPT0WU
SF268 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEGxOVEh|ryP MlXLV2FPT0WU
HD-MY-Z NIDXVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7ncWlPUUN3ME2wMlAyOTZ|IN88US=> MULTRW5ITVJ?
DOHH-2 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnxVpNPUUN3ME2wMlAyOjB|IN88US=> NEfCPXBUSU6JRWK=
SCC-3 M3uxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ftWmlEPTB;MD6wNVIxPCEQvF2= NEPuSo1USU6JRWK=
ST486 NGD1W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf5blVKSzVyPUCuNFEzODRizszN MknIV2FPT0WU
NALM-6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfwW4E5UUN3ME2wMlAyOjF2IN88US=> NVP0U|R1W0GQR1XS
NCI-H1436 M{HXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj2[pBXUUN3ME2wMlAyOjNzIN88US=> M3LqcnNCVkeHUh?=
KE-37 NWrXcYZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrjWXBKSzVyPUCuNFEzOzRizszN MX7TRW5ITVJ?
RPMI-8402 NFzjWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEGyOVYh|ryP MYLTRW5ITVJ?
RXF393 M3fLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvkR29KSzVyPUCuNFEzPTdizszN M{nGS3NCVkeHUh?=
KARPAS-45 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvsWYRKSzVyPUCuNFEzPyEQvF2= NXjHfHRwW0GQR1XS
HOP-62 M3PxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEGyO|Yh|ryP M1rzTXNCVkeHUh?=
ES1 NH3uVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPiUXpHUUN3ME2wMlAyOjh6IN88US=> MXLTRW5ITVJ?
L-363 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fzSGlEPTB;MD6wNVM2OSEQvF2= NXTKRmZPW0GQR1XS
GI-1 NXHobGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn4PJh5UUN3ME2wMlAyOzd|IN88US=> NEfFVVhUSU6JRWK=
CTV-1 NVn4UmUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T2b2lEPTB;MD6wNVQ4QCEQvF2= MXrTRW5ITVJ?
TE-5 NH:xNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF23R3VKSzVyPUCuNFE1QTZizszN M{nTU3NCVkeHUh?=
SNU-C2B Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnScZY2UUN3ME2wMlAyPDl4IN88US=> M4jxfnNCVkeHUh?=
K-562 NInWb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjGdJZKSzVyPUCuNFE2OTZizszN M1;RcnNCVkeHUh?=
SNB75 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3P[FhWUUN3ME2wMlAyPTRizszN Mm\OV2FPT0WU
MOLT-13 M33sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDxTWM2OD1yLkCxOlM4KM7:TR?= Mnm0V2FPT0WU
LS-123 NVqxbFJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rhVGlEPTB;MD6wNVY3PCEQvF2= NYDkNld{W0GQR1XS
NCI-SNU-5 M33rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfZTWM2OD1yLkCxO|AyKM7:TR?= MmXNV2FPT0WU
Daudi Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEG3NFgh|ryP MUPTRW5ITVJ?
A253 NWHwdGVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv0TWM2OD1yLkCxO|M5KM7:TR?= MnnBV2FPT0WU
TGBC1TKB NF\CSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvufpM3UUN3ME2wMlAyPzV{IN88US=> MnrLV2FPT0WU
SJSA-1 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj4R|VKSzVyPUCuNFE4PjdizszN M4r6VHNCVkeHUh?=
NCCIT NFrHdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLKTWM2OD1yLkCxO|Y6KM7:TR?= NU\mXYZpW0GQR1XS
NCI-H69 M{jDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEG3O|gh|ryP MojKV2FPT0WU
SH-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnGUWxMUUN3ME2wMlAyQDl3IN88US=> NHzXTWFUSU6JRWK=
HCC1187 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEG5NlQh|ryP NFzPflFUSU6JRWK=
HCC1599 NUnRU4Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3xZplKSzVyPUCuNFIxOiEQvF2= MXvTRW5ITVJ?
ONS-76 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEflZ4NKSzVyPUCuNFIxOzZizszN MWrTRW5ITVJ?
KU812 NYfhWJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HtfWlEPTB;MD6wNlA{QSEQvF2= MorkV2FPT0WU
ML-2 NX:2VZUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMEKwOFch|ryP NXu3[o1qW0GQR1XS
HCE-T NFf2eolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4POeGlEPTB;MD6wNlA6OiEQvF2= NHjWV3JUSU6JRWK=
NCI-H446 M2XBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO3[|lKSzVyPUCuNFIyOTJizszN NGjGNnFUSU6JRWK=
RPMI-6666 NVP1R3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKzPFRKUUN3ME2wMlAzOTR7IN88US=> M2rLeHNCVkeHUh?=
MOLT-16 NH7z[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\NOWlEPTB;MD6wNlE2OyEQvF2= M2Lp[HNCVkeHUh?=
JiyoyeP-2003 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlraTWM2OD1yLkCyNVc3KM7:TR?= MVjTRW5ITVJ?
MHH-PREB-1 M13PeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj3fFZKSzVyPUCuNFIyQTFizszN M1myO3NCVkeHUh?=
MC-CAR NX\tbZlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEKzNlYh|ryP MVzTRW5ITVJ?
BC-3 MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMEKzOFQh|ryP NEfBV4hUSU6JRWK=
KINGS-1 NEDGOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH6VXlUUUN3ME2wMlAzOzV3IN88US=> MV3TRW5ITVJ?
PF-382 M4i4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LKbWlEPTB;MD6wNlM4QCEQvF2= M33ze3NCVkeHUh?=
J-RT3-T3-5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnLTWM2OD1yLkCyN|g{KM7:TR?= MWDTRW5ITVJ?
SF539 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEK0NFEh|ryP NUewPVVlW0GQR1XS
LB831-BLC M4D1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTDZ2pIUUN3ME2wMlAzPDh3IN88US=> MYjTRW5ITVJ?
DMS-114 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33O[GlEPTB;MD6wNlUxOiEQvF2= NHqyW41USU6JRWK=
LB1047-RCC M4XOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEK1NUDPxE1? NYjqbY5sW0GQR1XS
LB771-HNC M4rofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PR[2lEPTB;MD6wNlU{PCEQvF2= MXTTRW5ITVJ?
BB65-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\aNmFKSzVyPUCuNFI2OzRizszN NH6xSItUSU6JRWK=
BV-173 M2fIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j6emlEPTB;MD6wNlU2PCEQvF2= MlO4V2FPT0WU
ARH-77 M1TDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn3TWM2OD1yLkCyOlAyKM7:TR?= Mnf0V2FPT0WU
IST-MEL1 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;pXZNKSzVyPUCuNFI3OjNizszN MnnjV2FPT0WU
NB1 NW\vW5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LGZmlEPTB;MD6wNlY5PyEQvF2= NV\X[nlHW0GQR1XS
EoL-1-cell Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ITWM2OD1yLkCyOlg5KM7:TR?= M4HKcHNCVkeHUh?=
KY821 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1izeGlEPTB;MD6wNlY6PyEQvF2= MnfzV2FPT0WU
CMK NYrqcJFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXybWRKSzVyPUCuNFI4OzRizszN MkjTV2FPT0WU
NCI-H2126 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGyTWM2OD1yLkCyO|Y5KM7:TR?= MUfTRW5ITVJ?
NCI-H526 NWr3VoRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPiTWM2OD1yLkCyPFkyKM7:TR?= MkTDV2FPT0WU
COLO-684 NX;1fW1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEK5NFgh|ryP NIDFellUSU6JRWK=
NCI-H747 NFTHblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEK5N|Mh|ryP M4jmXnNCVkeHUh?=
JAR M{LHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrMWXhzUUN3ME2wMlAzQTR4IN88US=> NE[0NphUSU6JRWK=
MEG-01 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\0TWM2OD1yLkCyPVc5KM7:TR?= M1TPVHNCVkeHUh?=
MONO-MAC-6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG3d41QUUN3ME2wMlA{ODJ|IN88US=> NEm5OJZUSU6JRWK=
IST-SL1 NFrJXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofiTWM2OD1yLkCzNFQzKM7:TR?= M3nFbHNCVkeHUh?=
CPC-N MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH1WFZyUUN3ME2wMlA{ODd7IN88US=> NYL0dlFwW0GQR1XS
NCI-H1963 MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6yWmlYUUN3ME2wMlA{OTNzIN88US=> MVTTRW5ITVJ?
K052 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK1TWM2OD1yLkCzNlQ4KM7:TR?= M1rWTnNCVkeHUh?=
KM-H2 NV;qS3VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW0TWM2OD1yLkCzN|A4KM7:TR?= NYq2cIY2W0GQR1XS
TE-12 NET3b4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nVRmlEPTB;MD6wN|MxQSEQvF2= MoLIV2FPT0WU
TK10 NFjYdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHPTWM2OD1yLkCzN|U3KM7:TR?= MmHOV2FPT0WU
NMC-G1 M4LTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnXTWM2OD1yLkCzOFUzKM7:TR?= NEfCfmRUSU6JRWK=
no-11 M17nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX74TpNUUUN3ME2wMlA{PDd6IN88US=> M3nZSXNCVkeHUh?=
NCI-H524 M2GxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX0TVd2UUN3ME2wMlA{PTJ7IN88US=> NYraOIdZW0GQR1XS
MHH-CALL-2 NHHFTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEO1OlIh|ryP M2jZ[3NCVkeHUh?=
GB-1 M4DldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEO2JO69VQ>? NVLXWoZGW0GQR1XS
OPM-2 Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULqOlJiUUN3ME2wMlA{Pjd|IN88US=> NEnSW|BUSU6JRWK=
RH-1 M3LwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XkUGlEPTB;MD6wN|gyQSEQvF2= MYjTRW5ITVJ?
NCI-H64 M4HTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEO4OVch|ryP NXr3TZc3W0GQR1XS
EVSA-T NWnHTpVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrrSY5qUUN3ME2wMlA{QTJ|IN88US=> NGH0No1USU6JRWK=
KARPAS-299 NGDVOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInsZ2ZKSzVyPUCuNFM6QCEQvF2= M4nyUnNCVkeHUh?=
MZ7-mel M2rnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDETWM2OD1yLkC0NFQh|ryP MV\TRW5ITVJ?
LB373-MEL-D NU\Wd|FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfKTmZZUUN3ME2wMlA1OTB3IN88US=> NUHkeZpiW0GQR1XS
HEL NGjrd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7JTWM2OD1yLkC0NVQh|ryP MXzTRW5ITVJ?
SW872 M{LR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfpPHhQUUN3ME2wMlA1OjFizszN M1TSfnNCVkeHUh?=
DU-4475 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PidWlEPTB;MD6wOFI1PCEQvF2= M3fO[3NCVkeHUh?=
IST-SL2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS5d5RKSzVyPUCuNFQzPzVizszN MoHYV2FPT0WU
NCI-H82 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjXfnlKSzVyPUCuNFQ{ODdizszN MYLTRW5ITVJ?
LC4-1 NIDMXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr1WIJOUUN3ME2wMlA1OzVzIN88US=> M{nCO3NCVkeHUh?=
HDLM-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMESzPVIh|ryP NFriVlRUSU6JRWK=
MMAC-SF MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fCVmlEPTB;MD6wOFU{PCEQvF2= MoXFV2FPT0WU
L-540 NFntdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMES2N|kh|ryP NHnIc|hUSU6JRWK=
MZ2-MEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMES3OFIh|ryP MlXJV2FPT0WU
LU-134-A M2\6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTGTWM2OD1yLkC0O|c{KM7:TR?= M3T5T3NCVkeHUh?=
UACC-257 M3zZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXzV4xKSzVyPUCuNFQ5PDlizszN NU\mNmg3W0GQR1XS
NCI-H1581 NGjXemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvoTWM2OD1yLkC0PVU{KM7:TR?= NXzSbJM6W0GQR1XS
NB17 NIHISoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fqdWlEPTB;MD6wOFk4QSEQvF2= MV;TRW5ITVJ?
SBC-1 NIHLV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zOS2lEPTB;MD6wOVA1OiEQvF2= NEC2OoVUSU6JRWK=
TALL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TkbWlEPTB;MD6wOVA1PSEQvF2= MVTTRW5ITVJ?
NCI-H1304 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2TWM2OD1yLkC1NlA5KM7:TR?= NWTrV|Y5W0GQR1XS
NEC8 NV\2VY9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rxdmlEPTB;MD6wOVI5PiEQvF2= MnO2V2FPT0WU
CAL-148 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D6R2lEPTB;MD6wOVQ{QSEQvF2= NXzUW|l3W0GQR1XS
CGTH-W-1 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP4WGxKSzVyPUCuNFU1PDlizszN NHfPeJVUSU6JRWK=
NCI-H889 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLPRnhCUUN3ME2wMlA2PTl{IN88US=> MnLQV2FPT0WU
GR-ST MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEW2NlEh|ryP NGXpXYZUSU6JRWK=
KARPAS-422 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDiTWM2OD1yLkC1OlUh|ryP M2XydHNCVkeHUh?=
RPMI-8866 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS3R5JoUUN3ME2wMlA2PzF{IN88US=> NIj5TYdUSU6JRWK=
SCLC-21H MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofzTWM2OD1yLkC1PFg1KM7:TR?= M2[3VnNCVkeHUh?=
COR-L88 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4njOGlEPTB;MD6wOVkzPyEQvF2= M{XJfnNCVkeHUh?=
LU-139 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIThd3dKSzVyPUCuNFU6QDZizszN Mo\ZV2FPT0WU
SF126 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv3eG03UUN3ME2wMlA3OTN|IN88US=> NI\KPJBUSU6JRWK=
NCI-H1882 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXiUFBXUUN3ME2wMlA3PDJ2IN88US=> NYq0b|l6W0GQR1XS
EW-24 M{TFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuxTWM2OD1yLkC2OFg{KM7:TR?= NVLPNFNHW0GQR1XS
CP67-MEL NIXDPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nVXWlEPTB;MD6wOlgyKM7:TR?= Mkj6V2FPT0WU
DG-75 NFvpOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwME[4PVkh|ryP MlPVV2FPT0WU
LOXIMVI MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hmb2lEPTB;MD6wO|AzQCEQvF2= NYjSRpRRW0GQR1XS
HH MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hhb2lEPTB;MD6wO|E2PyEQvF2= NXvpW5ZuW0GQR1XS
K5 NHPRfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnP[WdSUUN3ME2wMlA4OjJ4IN88US=> MlvIV2FPT0WU
EC-GI-10 NH2wVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvTWM2OD1yLkC3NlU4KM7:TR?= NIPjVYRUSU6JRWK=
SK-N-DZ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEezNFch|ryP NYXCS2RnW0GQR1XS
A3-KAW M33FXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjHcpVKSzVyPUCuNFc{PTFizszN MYLTRW5ITVJ?
MLMA NGfub3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEe0OlUh|ryP M4fNOHNCVkeHUh?=
LB996-RCC Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEe3NFch|ryP NXnzVnVwW0GQR1XS
OS-RC-2 NVjYbZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPUTWM2OD1yLkC3O|Q5KM7:TR?= MVPTRW5ITVJ?
CTB-1 NIKwcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17OPGlEPTB;MD6wO|gyKM7:TR?= Mn;UV2FPT0WU
IST-MES1 NWLyNnBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvkPWtKSzVyPUCuNFc6OTJizszN NIXRWGJUSU6JRWK=
LS-1034 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vvUmlEPTB;MD6wPFA{PSEQvF2= M1;TcHNCVkeHUh?=
HT MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrrSVY{UUN3ME2wMlA5ODh4IN88US=> MVHTRW5ITVJ?
NCI-H2141 NFnFdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\rPGlEPTB;MD6wPFEh|ryP NYXwUJppW0GQR1XS
LB2518-MEL NEC1S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMEixOFEh|ryP NWriN2NbW0GQR1XS
GI-ME-N Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEi0OVIh|ryP M{S5WHNCVkeHUh?=
TGW MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEi2NFch|ryP MlLaV2FPT0WU
SK-NEP-1 NWTvXJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEi2OFEh|ryP NHfmXldUSU6JRWK=
NOMO-1 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEmyO|Uh|ryP MVPTRW5ITVJ?
ES6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHHZ4gzUUN3ME2wMlA6PTh7IN88US=> MojnV2FPT0WU
NCI-H209 NUDRW5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PZUGlEPTB;MD6wPVc5PiEQvF2= NEHJ[|hUSU6JRWK=
GAK NUSxPZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\GemlEPTB;MD6xNFE3KM7:TR?= MoTCV2FPT0WU
BC-1 M3nMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;XNllUUUN3ME2wMlExOzZzIN88US=> MmK5V2FPT0WU
KLE NFzqSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPMZ2dDUUN3ME2wMlExPDR|IN88US=> M3\TcHNCVkeHUh?=
EW-3 NEnqeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLle2FKSzVyPUCuNVA6QCEQvF2= MnP6V2FPT0WU
NKM-1 NEfW[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzzSYJ1UUN3ME2wMlEyOSEQvF2= NFTsT3NUSU6JRWK=
D-336MG M2nDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPad3RKSzVyPUCuNVEzPDRizszN NVrOeGs5W0GQR1XS
NB69 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\6XWpKSzVyPUCuNVE{ODFizszN NU\1bll[W0GQR1XS
D-263MG Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDhPVVZUUN3ME2wMlEyPzF{IN88US=> MV3TRW5ITVJ?
KP-N-YS NWruXXNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rpVWlEPTB;MD6xNlI6OSEQvF2= MlPTV2FPT0WU
NCI-H1155 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZd3FKSzVyPUCuNVI2PThizszN NEX1cJVUSU6JRWK=
BOKU NYXuOVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMUK1O|kh|ryP MmDKV2FPT0WU
LAMA-84 M4jWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfrVmVKSzVyPUCuNVI6QSEQvF2= M4LaZnNCVkeHUh?=
Raji MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{foWGlEPTB;MD6xN|EyPyEQvF2= M2jxc3NCVkeHUh?=
LU-65 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnHVlBKSzVyPUCuNVM{ODdizszN MnXIV2FPT0WU
NCI-H187 NHrTSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXyTWM2OD1yLkGzPVI1KM7:TR?= M1nuPXNCVkeHUh?=
GCIY NFzLNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CzUWlEPTB;MD6xOFkxOSEQvF2= MknOV2FPT0WU
NCI-H2107 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW2TWM2OD1yLkG1NFgh|ryP MmrqV2FPT0WU
NCI-H1522 NF\XOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMUWyOlYh|ryP M4fU[XNCVkeHUh?=
NB6 NI\zTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMUW2NlMh|ryP Mn7KV2FPT0WU
EM-2 NIPnVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln5TWM2OD1yLkG1O|A3KM7:TR?= MkXaV2FPT0WU
HCC2218 M1XQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC2OFlKSzVyPUCuNVU6QCEQvF2= NWTwT|R7W0GQR1XS
NCI-H748 NUm0TGV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i2OmlEPTB;MD6xOlM4PiEQvF2= MXPTRW5ITVJ?
MS-1 M4Xue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7TTWM2OD1yLkG2OVM4KM7:TR?= NGe2SWVUSU6JRWK=
NB5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TCS2lEPTB;MD6xOlU6PyEQvF2= M4r6c3NCVkeHUh?=
OMC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHiS3JKSzVyPUCuNVY3QDhizszN MYrTRW5ITVJ?
NCI-H345 NHjsfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMU[5Nlgh|ryP MoLPV2FPT0WU
L-428 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;5cGlEPTB;MD6xOlk1PSEQvF2= NEfsSllUSU6JRWK=
SCH MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3pNWREUUN3ME2wMlE5Pjh3IN88US=> M4Wwe3NCVkeHUh?=
NCI-H1417 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECydFFKSzVyPUCuNVkzOjdizszN NUfhXmszW0GQR1XS
COLO-320-HSR NXXjU5dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv1WVlKSzVyPUCuNVk2OzJizszN NVXVWpNtW0GQR1XS
BT-474 MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3naXWlEPTB;MD6yNFg6OiEQvF2= MYnTRW5ITVJ?
GDM-1 NXrRd45vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjTZ3JKSzVyPUCuNlE6PzFizszN NGXLTlJUSU6JRWK=
NCI-H2196 NXjW[WJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMkKyN|Uh|ryP NFmx[5pUSU6JRWK=
KP-N-RT-BM-1 Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXtWldKSzVyPUCuNlI{PDlizszN NXnwZ216W0GQR1XS
KNS-81-FD NEHqe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMkK5OVgh|ryP M4HsVHNCVkeHUh?=
COLO-668 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrzTWM2OD1yLkKzOlc2KM7:TR?= MWDTRW5ITVJ?
C2BBe1 NYLY[|hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2TWM2OD1yLkK2O|Q4KM7:TR?= MWTTRW5ITVJ?
Ramos-2G6-4C10 M3LzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXzTWM2OD1yLkK2PVU1KM7:TR?= NFXlSotUSU6JRWK=
CAS-1 NX\HTG96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXhdIJsUUN3ME2wMlI4ODl4IN88US=> NFjWSpBUSU6JRWK=
GOTO MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3D[WZ5UUN3ME2wMlI4QDl2IN88US=> NF;rXFNUSU6JRWK=
LP-1 NVr0UWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMkiwOVch|ryP MU\TRW5ITVJ?
NCI-SNU-1 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;VcGlEPTB;MD6yPVQzOiEQvF2= NHTRNGpUSU6JRWK=
EB-3 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fSNWlEPTB;MD6yPVk4QSEQvF2= MVTTRW5ITVJ?
MHH-NB-11 NVjWVYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHGT5ZjUUN3ME2wMlMxPDB{IN88US=> MXzTRW5ITVJ?
SK-N-FI M2nJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwM{G2PVIh|ryP NV\sd452W0GQR1XS
HCC2157 NVj6O4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwM{O5NVMh|ryP M1[xTXNCVkeHUh?=
SIMA NXz6d3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO4WFJKSzVyPUCuN|Q2QDFizszN NIT5UXhUSU6JRWK=
MDA-MB-134-VI MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XwRmlEPTB;MD6zOlkzQCEQvF2= NVjyNYZOW0GQR1XS
NCI-H1694 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml75TWM2OD1yLkO3JO69VQ>? MnWwV2FPT0WU
EHEB NHrGbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwM{mwPFUh|ryP NWPuZmR2W0GQR1XS
U-266 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITXZ2VKSzVyPUCuN|k5PDZizszN NYrJUWhOW0GQR1XS
LC-1F NXP0dVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nRXmlEPTB;MD60N|c3PSEQvF2= NUDCWGNLW0GQR1XS
SHP-77 NHfPe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPhO2x[UUN3ME2wMlQ4QDV3IN88US=> MkTmV2FPT0WU
LS-513 NETTbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTSN4JmUUN3ME2wMlQ6OzB5IN88US=> NX:5[XpQW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 2年-20℃
6月-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
エタノール 18 mg/mL (21.07 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

文献中の引用 (16)

Frequently Asked Questions

  • Question 1
    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

    Answer: Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine sulfate

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ